Skip to main content

8 Result(s)

within M Ychou Remove this filter Medicine & Public Health Remove this filter Oncology Remove this filter

and

  1. No Access

    Chapter and Conference Paper

    Combination of 5-FU, Leucovorin and Cisplatin (CDDP): an efficient low-toxic chemotherapy in advanced gastric adenocarcinoma

    Metastatic gastric cancer remains a frequent disease with spontaneous median survival of about 6 months [1]. FAM regimen (5-FU, Doxorubicin and Mitomycin) was until the nineteens, considered as standard treatm...

    M. Ychou, Y. Fedkovic, A. Christopoulou, B. Saint-Aubert… in Cancer Treatment An Update (1994)

  2. No Access

    Article

    High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

    Abstract

    M. Ychou, J. Raoul, F. Desseigne, C. Borel… in Cancer Chemotherapy and Pharmacology (2002)

  3. No Access

    Article

    Le point sur la prise en charge des cancers digestifs

    M. Ychou, M. Ducreux in Oncologie (2008)

  4. No Access

    Article

    Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques

    Malgréde récents progrés dans la prise en charge des adénocarcinomes œsogastriques (AOG), leur mortalitéreste élevée et leur traitement est encore un véritable challenge pour les oncologues. Le traitement chir...

    E. Samalin, M. Ychou in Oncologie (2008)

  5. No Access

    Article

    Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases

    To assess the rate of R0 resection of liver metastases achieved after chemotherapy with FOLFIRINOX.

    M. Ychou, F. Viret, A. Kramar, F. Desseigne… in Cancer Chemotherapy and Pharmacology (2008)

  6. No Access

    Article

    Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

    Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors.

    T. Mazard, M. Ychou, S. Thezenas, S. Poujol… in Cancer Chemotherapy and Pharmacology (2012)

  7. No Access

    Article

    Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

    Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an ...

    L. Peuvrel, C. Bachmeyer, Z. Reguiai, J. B. Bachet, T. André… in Supportive Care in Cancer (2012)

  8. No Access

    Article

    Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

    Cutaneous adverse events induced by epidermal growth factor receptor (EGFR) inhibitors can hamper the patients' quality of life. The aim of our work was to draft an algorithm for the optimised management of th...

    Z. Reguiai, J. B. Bachet, C. Bachmeyer, L. Peuvrel… in Supportive Care in Cancer (2012)